Advanced Proteome Therapeutics (TSXV:APC)


Advanced Proteome Therapeutics Corporation is engaged in the production and development of therapeutic drugs for treating cancer. The biotechnology company has reportedly developed an industry-leading approach to streamline the effect of anti-cancer drugs on cancer cells.

The firm claims its approach is an alternative to the chemotherapy that is known for various side effects on the human body. It says that its targeted therapy spares the healthy human cells and destroy the cancer cells.

The biotech firm claims to focus on creating new antibodies drug with higher specificity, greater potency and lower side-effects as compared to the existing therapies in the healthcare market.

The company aims to revolutionize the anti-cancer therapeutic market with its proprietary drug. It adds that the cancer treatment has evolved over the centuries since late 1800s when the only way to treat the disease was surgery.

In the early 1900s, Radiation therapies were introduced to treat cancer followed by chemotherapy and hormone treatments in the mid-1900s, it claims.

The biotech firm further says that with the advent of targeted medicines along with chemotherapy and hormone treatment revolutionized the anti-cancer market in late 1900s and early 2000s. Presently, the industry is welcoming a new form of Antibody drug Conjugate (ADC) and immune-oncology therapies, it claims.

The firm has reportedly developed this ADC targeted therapy using protein modification technology. In addition, it claims to have partnered with acclaimed academic and industrial experts to prove the efficacy of its product pipeline.

The biotech firm affirms that despite a global clinical development of ADC therapy, the industry still lacks the required effectiveness, clinical potential and ease of manufacturing.

Advanced Proteome Therapeutics claims to have developed a superior linker technology that optimizes the ADC products and minimizes the associated costs.

The company also aims to augment its commercial and R&D platform to develop the traditional ADC therapy. Advanced Proteome Therapeutics claims to apply their site-selective technology-UAC, to label the antibodies with customizable linker technology.

The British Columbia-based company also aims to advance the labeling technology by licensing of its linker technology to related companies so that the latter can develop their own ADC product candidates.

The company has reportedly partnered with Centre for the Commercialization of Antibodies and Biologics (CCAB), Toronto Recombinant Antibody Centre (TRAC), University of Toronto and Noira Therapeutics Inc.

Contact Information

company address 104 - 8337 Eastlake Drive Burnaby, British Columbia V5A 4W2

company phone604 690-3797

company email[email protected]

company website

Similar Companies

Load More
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK